Diagnostic value of combined evaluation of neopterin and anti-DNA antibody levels for assessment of disease activity in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 18, Issue 6, 2000, Pages 699-705

  Nagy, G ^a   Brozik, M ^a   Tornoci, L ^a   Gergely, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anti DNA; Neopterin; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; NEOPTERIN;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL EXAMINATION; COMPLEMENT HEMOLYSIS TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNODIFFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; DNA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEOPTERIN; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0033645089     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Use and abuse of eight widely-used diagnostic procedures in clinical immunology: A WHO memorandum
2. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus
3. Routine immunologic tests in systemic lupus erythematosus: Is there a need for more studies?
4. Assessment of lupus: Where are we now?
5. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study
6. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus
7. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus
8. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus
9. Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application
10. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro
11. Concentrations of neopterin and biopterin in serum from patients with rheumatoid arthritis or systemic lupus erythematosus and in synovial fluid from patients with rheumatoid or osteoarthritis
12. Urinary neopterin in patients with systemic lupus erythematosus
13. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: Comparisons with serum SIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products
14. Urine neopterin: A new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus
15. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus
16. Usefulness of procalcitonin for differentation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection
17. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus
18. Highly sensitive, specific enzyme-linked immunosorbent assay of neopterin and biopterin in biological samples
19. Serum soluble interleukin 2 receptor in systemic lupus erythematosus: Effects of disease activity and infection
20. The soluble interleukin-2 receptor in rheumatic disease
21. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases
22. Comparative value of urinalysis, urine cytology and urine sIL2R in the assessment of renal disease in patients with systemic lupus erythematosus (SLE)
23. Soluble interleukin-2 receptors in sytemic lupus erythematosus
24. Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis
25. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis
26. Simultaneous use of multipie serologic tests in assessing clinical activity in systemic lupus erythematosus
27. DNA antibodies and complement in SLE patients. A follow-up study
28. A new specific assay for the detection of DNA immune complexes: Its relevance in SLE
29. Useful laboratory measurements in the management of systemic lupus erythematosus
30. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity
31. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE)
32. The value of complement activation products in the assessment of systemic lupus erythematosus flares
33. Derivation of the SLEDAI: A disease activity index for lupus patients
34. Kinetic Analysis of immune complex solubilization: Complement function in relation to disease activity in SLE
35. Basic principles of ROC analysis